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Study design: Cell transplantation strategies are gaining increasing interest for spinal cord injury (SCI)
with the objective of promoting spinal cord repair. To avoid allogenic graft rejection, an adequate
immune suppression is required, and one of the most potent and commonly used immunosuppressives
is cyclosporin A (CsA). In SCI, permanent sensory motor loss is combined with modifications of drug
absorption, distribution and elimination.
Objectives: The objectives of this study were to thoroughly explore histological and functional
outcomes of CsA treatment in a rat model of spinal cord compression.
Setting: Experiments were carried out at the Institute for Neurosciences of Montpellier (France), the
Integrative Biology of Neurodegeneration Laboratory (Spain) and in the Novartis Institutes for
BioMedical Research (Switzerland) for CsA blood concentration determination.
Methods: We first evaluated histological outcomes of CsA treatment on kidneys and spinal cord after
SCI. We then investigated whether SCI modified CsA blood concentration. Finally, using behavioral
analysis, we assessed the potential CsA impact on functional recovery.
Results: When spinal-cord-injured rats were treated with a CsA dose of 10mgkg1 per day, we
observed deleterious effects on kidneys, associated with modifications of CsA blood concentration.
Adding an antibiotic treatment reduced kidney alteration without modifying CsA blood concentration.
Finally, we showed that CsA treatment per se modified neither functional recovery nor lesion extension.
Conclusion: This study pinpoints the absolute requirement of careful CsA monitoring in the clinical
setting for patients with SCI to minimize potential unexpected effects and avoid therapeutic failure.
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Introduction
Cell transplantation approaches are promising potential
therapies for central nervous system disorders. This is
particularly true for spinal cord injury (SCI) that leads to
permanent sensory motor loss with no current therapy. In
SCI, cell grafting, among other objectives such as replace-
ment of lost cells, may be used as a tool to provide trophic
support to preserve undamaged tissues and promote spinal
cord repair (for review see Barnabe-Heider and Frisen1).
To avoid allogenic graft rejection, an immune suppression is
required and one of the most commonly used immune
suppressants is cyclosporin A (CsA). Besides complete or
partial deprivation of sensory and motor functions, SCI
induces several systemic and metabolic alterations such as
reduction of hepatic microvascular blood flow.2 Owing to
modification in drug absorption, distribution and elimina-
tion, SCI alters CsA bioavailability in a complex time- and
route-administration-dependent manner.3 At an acute stage
after spinal cord injury, CsA availability is either increased or
decreased when delivered intraperitonealy or orally. At a
chronic stage, no difference is observed whatever the
administration route.4 Increased availability of CsA may
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result from an impairment in drug clearance,2,4 whereas
decreased bioavailability may be because of modification in
gastrointestinal tract absorption.4
Besides its effects in prevention of allograft rejection, CsA
shows various adverse side effects such as nephrotoxicity5
and leads to reduction in both renal blood flow and
glomerular filtration rate. Conversely, CsA has been reported
to be neuroprotective following SCI.6 Rats subjected to spinal
compression7 or contusion8 present a better motor outcome
when treated with CsA. However, in other studies, absence of
CsA neuroprotection at both behavioral and morphological
levels was reported after SCI.9–10
In the perspective of possible clinical application of
allogenic cell transplantation after SCI, we investigated
outcomes of CsA treatment in a well-defined rat model of
spinal cord compression.11
Results
Combined SCI and CsA immunosuppressive therapy induced
severe kidney alterations
Male rats that underwent spinal cord compression and were
treated with CsA presented exacerbated suffering. This was
strikingly different to SCI-only or to uninjured rat (sham)
treated with the same CsA dose. Forensic analysis revealed
major kidney alterations; all ‘SCI-CsA’ animals developed
major hydronephrosis (Figure 1a) and/or ulceration and
necrosis (Figure 1b), whereas all ‘sham’, ‘injured-only’ and
‘CsA-only’ rats presented normal kidneys (Figures 1a and b).
SCI combined with CsA treatment induced prominent
glomerular (Figure 1d) and tubular (Figure 1f) changes with
respect to all other groups (Figures 1c and e). Severe
glomerular hydronephrosis (Figure 1d) associated with
periglomerular fibrosis (arrow, Figure 1d) was observed.
Moreover, tubular necrosis was associated with severe
constriction due to thickening of the tubular wall
(Figure 1f). Morphometric analysis of the median long-
itudinal section revealed dose–response kidney alterations;
70, 50 and 10% of the rats had normal kidneys in the 5, 7.5
and 10 mg kg1 per day groups, respectively, whereas 0, 40
and 60% of animals presented extremely severe kidney
alterations (scores 2þ3) in the same-dose group (Table 1).
Kidney alterations in the 10 mg kg1 per day group were
reduced by administration of gentamicin treatment and 75%
of the animals had normal kidneys (Table 1).
CsA blood concentration is modified by SCI
To determine whether deleterious effects of CsA on kidneys
in ‘SCI-CsA’ animals were correlated to a modification in
drug disposition, we carried out whole-blood CsA dosage
analysis. Daily subcutaneous injection of CsA started 2 days
before surgery; on the day of surgery, injection was
administered just after injury and CsA blood concentration
was analyzed 2 and 24 h after injury and concomitant
injection. Four groups of rats were used: rats with or without
(sham) SCI were injected with either NaCl or CsA
(10 mg kg1) (Table 2A). Sham and SCI rats injected with
NaCl presented the same zero CsA baseline level (Figure 2a).
At 2 h after injection, injured rats had a lower CsA blood
concentration (2.0±0.17 mM) than did sham animals
(2.56±0.21 mM) (Figure 2a). This difference was exacerbated
24 h after injection: injured rats had a CsA blood concentra-
tion of 1.34±0.09 mM and sham animals 1.98±0.19 mM
(Figure 2a). Even if CsA levels decreased over time (2 and
24 h) in sham rats (2.56 and 1.98 mM) and injured animals
(2.0 and 1.34 mM), they did not return to the baseline level
(Figure 2a). In the injured group, 48 h after injection, CsA
blood level almost dropped to baseline (1.98 mM) (Figure 2b).
CsA dose–response analysis in both sham and injured
animals using three CsA concentrations (5, 7.5 and
10 mg kg1; Table 2B) showed that, in the sham group, CsA
blood concentrations correlated with CsA doses (Figure 2c).
Conversely, SCI rats presented equivalent CsA blood con-
centrations (0.49±0.07 and 0.45±0.08 mM) for the 5 and
7.5 mg kg1 doses (Figure 2c). At 10 mg kg1, CsA concentra-
tion was 1.25±0.27 mM. Thus, CsA blood concentration was
lower in SCI animals for a CsA treatment of 7.5 and
10 mg kg1, at variance with the 5 mg kg1 dose (Figure 2c).
Combined antibiotic and immunosuppressive therapy reduced
kidney alterations without modifying CsA disposition
To minimize urinary tract infection, we combined treat-
ments with both CsA and gentamicin (2 mg kg1), and
evaluated the outcomes on kidneys and CsA blood level
(Table 2C). When gentamicin was added, 75% of animals
showed normal kidneys, 16% presented minor alterations
and only 9% presented more severe lesions (Table 1). CsA
disposition was not modified in either group; levels were
similar 24 and 48 h after injection (Figure 2d).
CsA treatment did not modify functional recovery and lesion
extension after SCI
The potential neuroprotective effect of CsA in SCI is under
debate.6–10,12,13 Therefore, we conducted an analysis of
functional locomotor and histopathological outcomes after
SCI using various CsA concentrations and a combined
treatment of CsA and gentamicin. Before injury, and for 7
(dose response) or 12 (combined treatment) days after injury,
we carried out functional tests for motor, sensory and reflex
recovery.11 We did not observe differences among the
Nacl-, 5- and 7.5 mg kg1-treated groups in any of the tests
(Supplementary Figure). Comparison of combined CsA–
gentamicin treatments with control did not reveal differ-
ences in motor and sensory recovery rates but bladder
recovery was significantly improved (Figure 3). We carried
out a histological analysis (Figure 4) and evaluated the lesion
area on a 2.5-cm spinal cord segment centered on the lesion.
For all time points analyzed (24 h, 1, 2 and 5 weeks), there
was no difference in lesion extension between groups.
At 24 h after SCI, approximately 90% of the tissue was
injured at the epicenter in both NaCl- (88.8±6.5%) and
CsA (91.5±3.1%)-treated groups (data not shown). No CsA
dose difference was detected in the percentage of injured
tissue at the epicenter (90.9±4.9 and 90.5±0.3% for 5 and
7.5 mg kg1, respectively; data not shown). At 2 weeks after
injury, damaged areas were similar in all groups (87.7±8.5,
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84.3±8.7 and 89.1±6.6 for NaCl, CsA 10 mg kg1 only and
CsA and gentamicin-treated animals, respectively; data
not shown). At 5 weeks after SCI, both antibiotic-only and
CsA–antibiotic groups presented the same area of damaged
tissue at the epicenter (75.8±12.5 and 80.8±8.1, respec-
tively; Figure 4f). The total lesion extension along the
rostrocaudal axis was similar in all groups for each time
point (Figure 4f).
Discussion
We observed deleterious effects on kidneys when CsA was
subcutaneously administered to spinal-cord-compressed rats.
Nephrotoxicity is a widely described side effect of CsA
treatment,5,14–15 but increased CsA nephrotoxicity has never
been reported in SCI. In our experiments, animals developed
major glomerular hydronephrosis, ulceration and tubular
necrosis that eventually led to death. In parallel, CsA blood
concentration was modified by SCI; not only did injured rats
present a lower CsA blood concentration compared with
Figure 1 Combined SCI and CsA treatment induced severe nephrotoxicity. (a, b) Macroscopic kidney views. (a) Internal and (b) external
sagittal view of kidneys from ‘injured-only’ (left) and ‘SCI-CsA’ rats (right). Kidneys of ‘injured-only’ rats appeared normal, whereas ‘SCI-CsA’
animals presented (a) major hydronephrosis and/or (b) ulceration and necrosis. (c–f) Light microscopic kidney sections (hematoxylin and
eosin; original magnification, 400). (c, e) ‘Injured-only’ animals. (d, f) ‘SCI-CsA’. (c, d) Renal glomeruli were normal in ‘injured-only’ rats (c),
whereas those from ‘SCI-CsA’ rats showed severe hydronephrosis and periglomerular fibrosis (d, arrow). (e, f) Renal proximal tubules were
normal in ‘injured-only’ animals. (e) Severe tubular atrophy and necrosis was observed in the ‘SCI-CsA’ group (f). Note that ‘sham’, ‘injured-
only’ and ‘CsA-only’ rats presented similar normal kidneys. For clarity, only pictures from ‘injured-only’ animals are presented. CsA: 10mgkg1.
Scale bar¼50mm.
Table 1 Morphometric quantification of kidney alterations
CsA (mg kg1 per day) Score
0 (%)
Score
1 (%)
Score
2 (%)
Score
3 (%)
5 70 30 0 0
7.5 50 10 30 10
10 10 30 20 40
10+gentamicin 75 16 9 0
Abbreviation: CsA, cyclosporin A.
Scores: 0, normal kidney; 1, between 5 and 40% of the increased median area
without ulceration or dilatation of the pyelocalyceal cavities; 2,440 % of the
increased area without ulceration and up to a 25 % increased in pyelocalyceal
cavities; 3, 440 % of the increased area associated with 425 % increase of
pyelocalyceal cavities or with ulceration. Gentamicin (2mg kg1 per day).
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sham animals but also, and unlike with sham rats, CsA blood
concentration did not correlate with CsA doses. CsA
pharmakokinetics is modified by SCI.3 in an administra-
tion-route manner.4 We observed a decreased CsA bioavail-
ability, as found when the drug is administered orally;14 this
may likely be because of preferential accumulation in organs,
as CsA-treated mice present a higher CsA concentration peak
in the spleen and in kidneys than in blood.16 Moreover,
CsA accumulates preferentially in organs susceptible to CsA
toxicity (brain, kidneys, liver, thymus and spleen) than in
resistant organs (heart, lungs and muscles).17 Modification of
CsA kinetics induced by SCI could therefore contribute to its
toxicity by means of increased retention and/or accumula-
tion in susceptible organs such as kidneys.
Urological infections are the most reported secondary
effects for SCI patients and immunosuppressive therapies
exacerbate infections. When animals were treated with
gentamicin, 75% of rats presented normal kidneys as
compared with 90% of kidney alterations without antibiotic
treatment. Gentamicin is known for its nephrotoxicity;
however, CsA–gentamicin treatments never enhanced kid-
ney alterations. Thus, kidney alterations most likely resulted
from combined urinary tract infection due to SCI and CsA
treatments; however, control of the infection reduced, if not
abrogated, CsA nephrotoxicity.
Cyclosporin neuroprotection after SCI has been reported
in some studies (for review see Rezzani15) but not in
others.9–10 When CsA is administered after spinal cord
contusion, improved motor function is reported.8 After
spinal cord compression, CsA treatment improves motor
performance but does not increase the extent of spared
tissues.7 Conversely, no improvement in motor perfor-
mance, or in the amount of spared cord tissue, is reported
after spinal cord contusion when CsA is administered before,
during or after injury.9–10 In our model of compression
injury, CsA treatment did not have a neuroprotective effect,
as it did not modify the functional recovery and the lesion
extension. The model and the severity of the lesion certainly
account for some of these discrepancies in the potential
neuroprotective effect of CsA. The strain of animal used, the
Table 2 animal assignments
Surgery Sham Compression
Treatment NaCl CsA (10mg kg1) NaCl CsA (10mg kg1)
(A) CsA blood concentration is modified by SCI
CsA blood concentration 2h 2h 24h 2h Surgery 2h 24 h 48h
Number of animals 6 6* 6* 6 7# 7# 7# 7
Killing and histology (24 h after SCI) (kidneys and spinal cord) Yes Yes Yes Yes
Surgery Sham Compression
(B) CsA dose response
Treatment: CsA (mg kg1) 5 7.5 10 5 7.5 10
Number of animals 5 5 5 5 5 5
CsA blood concentration 24 h after the last injection
Behavioral evaluation Daily for 12 days
Killing and histology (kidneys and spinal cord) 2 weeks after surgery
Surgery Compression Compression
Treatment:
CsA (10mg kg1)
Gentamicin (2mg kg1) NaCl+Gentamicin CsA CsA+Gentamicin CsA+Gentamicin NaCl+Gentamicin
(C) CsA and gentamicin treatments
Number of animals 6 6 6 8 7
CsA blood concentration 24 and 48h after last injection
Behavioral evaluation Daily for 12 days
Killing and histology (kidneys and spinal cord) 2 weeks after surgery 5 weeks after surgery
Abbreviations: CsA, cyclosporin A; SCI, spinal cord injury.
*and # different time points obtained with same animals.
(A) For CsA blood concentration analysis after SCI, we analyzed 32 animals. 12 animals had undergone a sham surgery (6 rats received NaCl and 6 CsA
(10mg kg1)). 13 animals had undergone a compression injury (6 rats received NaCl and 7 CsA (10mg kg1)), 7 other animals received CsA (10mg kg1) for
blood analysis at 48h. CsA blood concentration was analyzed at different time points after injection. For histological kidneys and spinal cord analysis animals were
killed 24 h after surgery. (B) For CsA dose response we analyzed 30 rats. 15 animals had undergone a sham surgery and received either different CsA doses (5, 7.5
and 10mgkg1; 5 animals per group) or NaCl. 15 animals that had undergone a compression injury were similarly treated (CsA: 5, 7.5 and 10mgkg1 or NaCl; 5
animals per group). CsA blood concentration was analyzed 24h after the last injection. Behavioral evaluation was carried out daily for 12 days. Animals were killed
2 weeks after surgery and histological analysis of kidneys and spinal cord were carried out. (C) For CsA and CsA–gentamicin combined treatments we analyzed 33
rats. They all had undergone spinal cord compression. 13 animals received a combined NaCl and gentamicin treatment, 6 received only CsA and 14 received a
combined CsA and gentamicin treatment. CsA blood concentration was analyzed 24 and 48h after the last injection. Behavioral evaluation was carried out daily for
12 days. 18 and 15 animals were killed 2 and 5 weeks after compression and histological analyses of kidneys and spinal cord were carried out. For all experiments,
treatments (NaCl, CsA and combined CsA–gentamicin) started 2 days before surgery.
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level of injury, the route, dose and frequency of CsA
administration may also have a significant effect.
One of the limitations of autologous grafting may be the
availability of a sufficient amount of cells to be grafted.
Indeed, delay in obtaining enough autologous cells to be
transplanted may be incompatible with the optimal time
window for treatment. In this case, heterologous grafting,
which requires immunosuppression, may become the only
possibility. In clinics, most drug regimens do not take into
consideration the specificity of SCI patients. However, SCI
influences drug disposition in a complex manner and may
thus predispose patients to adverse side effects. This points to
the absolute necessity not only to consider drug pharmaco-
kinetics but also to design unique protocols for SCI patients
that will require further prospective studies.
In conclusion, we show that (1) combined spinal cord
compression and CsA treatment induced deleterious effects
on kidneys that are reduced if not abrogated when an
antibiotic therapy is added; (2) SCI induced modification in
CsA blood concentration probably because of specific organ
retention; (3) gentamicin treatment had no effect on
CsA blood concentration; and finally (4) CsA showed no
neuroprotective effect in spinal cord compression.
Materials and methods
Animal, surgery, pharmacological treatments, CsA concentration
measurement
Experimental procedures followed the European legislation
for animal experimentation (86/609/EEC). All applicable
institutional and governmental regulations with regard to
the ethical use of animals were followed during the course of
this research. We used 8- to 9-week-old male Wistar rats
(Charles River, Lyon, France). Surgeries were conducted with
1 liter per min O2 supply and anesthesia was induced by
4% isoflurane and maintained at 2.5%.11 Compression
injury was carried out similarly to that described pre-
viously.11 A 2-French Fogarty catheter (Edwards Lifesciences,
Nyon, Switzerland) was introduced into the epidural space;
the balloon was positioned at thoracic level 8, inflated (15 ml)
and left in place for 5 min. Sham animals underwent the
same protocol, except for balloon inflation. Animals were
killed with an overdose of pentobarbital and perfused
transcardially with 4% paraformaldehyde (Table 2). For
histological studies, 2.5 cm spinal cord segments centered
on the lesion and kidneys were dissected, postfixed,
cryoprotected and embedded in Tissue-Tek OCT Compound
(Sakura Finetech, Zoeterwoude, The Netherlands).
Pharmacological treatment consisted of daily subcuta-
neous injection of CsA (Novartis, Basel, Switzerland) at 5,
7.5 and 10 mg kg1. CsA injection started 2 days before
surgery. Controls received the equivalent volume of NaCl
(Table 2). Antibiotic therapy consisted of daily i.m. injection
of gentamicin (2 mg kg1) for 7 days starting at the time
of surgery.
Blood was drawn under light isoflurane anesthesia in
heparin-rinsed tubes. Blood samples were spiked with a
structurally closely related internal standard (cyclic peptide
with one additional methyl group as compared with CsA),
lysed and deproteinated using acetonitrile, centrifuged, the
supernatant was evaporated and the pellet was redissolved in
Figure 2 CsA blood concentration is modified by SCI. (a) Cyclosporin A blood level in sham (uninjured) and SCI rats. At 2 and 24h after
injection, CsA blood levels were lower in rats that underwent SCI. CsA treatment: 10mgkg1. (b) Time course analysis of CsA blood
concentrations in SCI rats. At 48h after injection, CsA concentration almost returned to baseline. CsA treatment: 10mgkg1 (c) CsA dose–
response comparison between sham and injured rats. Analysis was carried out 24h after the last CsA injection. (d) Comparison of CsA blood
concentration in injured rats that received either CsA-only (10mgkg1) or combined CsA–gentamicin treatment (10 and 2mgkg1,
respectively). Statistical analysis: t test, *Po0.05 and **Po0.01; data represent the mean±s.e.m of at least six animals per group.
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60% methanol. This solution was separated on a Macherey-
Nagel Nucleodur Isis HPLC column (MACHEREY-NAGEL,
Du¨ren, Germany; particle size: 1.8 mm). The flow from the
HPLC system was directly introduced into the ion source of a
TSQ Quantum Ultra MS (Thermo Scientific, Waltham, MA,
USA) and subjected to atmospheric pressure electrospray
ionization. CsA was specifically detected with a parent-
parent scan of its sodiated molecular ion (MþNa)þ at m/z
1224.8. Quantification of blood levels of the parent com-
pound CsA was based on a seven-level calibration curve (in
triplicate) using blank rat blood samples spiked with stock
solutions of external and internal standards.
Behavioral monitoring
Before injury, and for 7 or 12 days after injury, functional
tests were carried out daily for motor, sensory and bladder
control as previously described.11 Motor response was
evaluated by three tests: open-field walking and inclined
plane for gross motor performance and a grid-navigation test
Figure 3 Combined CsA–gentamicin treatment did not modify functional recovery but improved bladder recovery after SCI. (a, b)
Locomotor outcomes after spinal cord compression of injured rats treated either with NaCl or with a combination of CsA-gentamicin.
(a) Open-field test before and during 12 days after compression for evaluation of gross motor function and (b) grid navigation test for
evaluation of fine motor coordination over a 50-cm horizontal runaway grid. No difference was observed between groups; they were both
severely impaired. Open-field walking on the horizontal plane ranges from no hind limb movement and no weight bearing (0) to normal
walking (6). Scores grid: 0 corresponds to hind limb drag without foot placement and 5 to normal walking to normal course over the grid with
toes gripping the wire. (c) Pain withdrawal was used to evaluate superficial sensory function. Scores range from normal response (0)
to hyperalgesia (4). No difference was observed between the two groups, they were both hyperalgesic. (d) Reflexes were evaluated by hind
limb withdrawal after manual extension; both groups presented similar deficits. Scores range from normal response (0) to hyper reaction (3).
(e, f) Autonomic function corresponds to bladder control. (e) Animals treated with a combined CsA–gentamicin cocktail regained a better
bladder control 7 days after injury than did control animals. (f) A higher percentage of animals treated with a combined CsA–gentamicin
cocktail regained bladder control 7 days after injury. Scores: no bladder control (0) and bladder control (1). (a–e) Statistical analysis: two-way
ANOVA, followed by Bonferroni’s multiple comparison test (**Po0.01; ***Po0.001). (f) w2-Test on the percentage of animals reaching a given
score was used (**Po0.01, ***Po0.001).
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for fine motor performance. Evaluation of sensory response
consisted of pain and heat withdrawal for superficial
function and proprioception for deep function. Reflexes
were evaluated by hind limb withdrawal after manual
extension and hind limb and toe extension when the animal
is picked up by the tail. Bladders were manually emptied
until subjects regained bladder function.
Histology and lesion extension
Lesion extension was observed on 12-mm-thick Luxol fast
blue-stained cryosections of the spinal cord; one section was
stained each 360 mm. Morphometric quantification was
carried out with MetaMorph software (MDS Analytical
Technologies, Toronto, Canada). Longitudinal kidney cryo-
sections (12 mm) were stained with hematoxylin and eosin.
Morphometric quantification of the median section was
performed on all kidneys and scored in four categories: 0,
normal kidney; 1, between 5 and 40% of increased area
without ulceration or pyelocalyceal cavities dilatation; 2,
440% of increased area and up to a 25% increase of
pyelocalyceal cavities, without ulceration; 3, 440% of
increased area associated with 425% increase of pyelocaly-
ceal cavities or with ulceration. In cases of asymmetric
degradation, the score of the worst kidney was considered.
All volumetric analyses were performed according to the
Cavalieri principle.18
Statistical analysis
CsA blood concentration: t-test, *Po0.05, **Po0.01,
***Po0.001. Means are presented with s.e.m. Behavioral
analysis and lesion extension (area under the curve): two-
way analysis of variance followed by Bonferroni’s multiple
comparisons; behavioral analysis: w2-test on the percentage
of animals rising over a given score (*Po0.05; **Po0.01;
***Po0.001). Lesion extension: at the epicenter, t-test
analysis was used.
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